Loading stock data…
Baxter International Inc. (BAX)
$24.86-0.97 (-3.76%)
Market ClosedLast close Sep 8
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Baxter International Inc. in the Healthcare sector is trading at $24.86 with a market capitalization of $13.8B. Wall Street consensus targets $28.73 (11 analysts), implying a +15.6% move over the next 12 months. The stock is currently 17% below its 52-week high of $30.00, remaining 22.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.96B↑ | $2.70B↓ | $2.97B↑ | $2.83B↑ | $2.81B |
| Gross Profit | $1.03B↑ | $891.00M↑ | $577.00M↓ | $950.00M↓ | $991.00M |
| Operating Income | $217.00M↑ | $66.00M↑ | -$244.00M↓ | $172.00M↓ | $191.00M |
| Net Income | $126.00M↑ | -$15.00M↑ | -$1.13B↓ | -$46.00M↓ | $91.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.80%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.13%
Volume
Today's trading volume
5.91M
Recent News
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.
3 Value Stocks We Keep Off Our Radar
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.
Will New Capital Markets And Chip Leaders On The Board Change IonQ's (IONQ) Narrative
In recent days, IonQ appointed two new board members, veteran finance executive Dr. Eric Ball and former SkyWater chairman and Samsung North America CEO Timothy Baxter, adding deep capital markets and semiconductor leadership experience to its governance. The combination of Ball’s large-scale financing and M&A track record with Baxter’s chip industry and go-to-market expertise could be important as IonQ integrates SkyWater and scales its merchant quantum supply ambitions. Next, we’ll...
3 Unpopular Stocks That Fall Short
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.